The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease
Open accessAbstract
Parkinson’s disease (PD) is characterized by dopaminergic neuronal loss in the substantia nigra pars compacta and intracellular inclusions called Lewy bodies (LB). During the course of disease, misfolded α-synuclein, the major constituent of LB, spreads to different regions of the brain in a prion-like fashion, giving rise to successive non-motor and motor symptoms. Etiology is likely multifactorial, and involves interplay among aging, genetic susceptibility and environmental factors. The prevalence of PD rises exponentially with age, and aging is associated with impairment of cellular pathways which increases susceptibility of dopaminergic neurons to cell death. However, the majority of those over the age of 80 do not have PD, thus other factors in addition to aging are needed to cause disease. Discovery of neurotoxins which can result in parkinsonism led to efforts in identifying environmental factors which may influence PD risk. Nevertheless, the causality of most environmental factors is not conclusively established, and alternative explanations such as reverse causality and recall bias cannot be excluded. The lack of geographic clusters and conjugal cases also go against environmental toxins as a major cause of PD. Rare mutations as well as common variants in genes such as SNCA, LRRK2 and GBA are associated with risk of PD, but Mendelian causes collectively only account for 5% of PD and common polymorphisms are associated with small increase in PD risk. Heritability of PD has been estimated to be around 30%. Thus, aging, genetics and environmental factors each alone is rarely sufficient to cause PD for most patients. PD is a multifactorial disorder involving interplay of aging, genetics and environmental factors. This has implications on the development of appropriate animal models of PD which take all these factors into account. Common converging pathways likely include mitochondrial dysfunction, impaired autophagy, oxidative stress and neuroinflammation, which are associated with the accumulation and spread of misfolded α-synuclein and neurodegeneration. Understanding the mechanisms involved in the initiation and progression of PD may lead to potential therapeutic targets to prevent PD or modify its course.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 2,868
The prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,825
Parkinson, J. (2002) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.14.2.223 · Cited by 1,628
Rotenone, Paraquat, and Parkinson’s Disease
Tanner, C. M., Kamel, F., Ross, G. W., Hoppin, J. A., Goldman, S. M., Korell, M., Marras, C., Bhudhikanok, G. S., Kasten, M., Chade, A. R., et al. (2011) · Environmental Health Perspectives · doi:10.1289/ehp.1002839 · Cited by 1,475
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228
A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci
Chang, D., Nalls, M. A., Hallgrímsdóttir, I. B., Hunkapiller, J., van der Brug, M., Cai, F., International Parkinson's Disease Genomics Consortium, 23andMe Research Team, Kerchner, G. A., Ayalon, G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3955 · Cited by 1,112
Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases
Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M., Wachter, S., Lorentzen, E., Duddy, G., Wilson, S., et al. (2016) · eLife · doi:10.7554/elife.12813 · Cited by 1,042
Goedert, M. (2015) · Science · doi:10.1126/science.1255555 · Cited by 976
Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein
Giasson, B. I., Forman, M. S., Higuchi, M., Golbe, L. I., Graves, C. L., Kotzbauer, P. T., Trojanowski, J. Q., & Lee, V. M.-Y. (2003) · Science · doi:10.1126/science.1082324 · Cited by 879
Parkinson Disease in Twins: An Etiologic Study
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 867
Association of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy
Baker, M., Litvan, I., Houlden, H., Adamson, J., Dickson, D., Perez-Tur, J., Hardy, J., Lynch, T., Bigio, E., & Hutton, M. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.4.711 · Cited by 781
Human iPSC-based modeling of late-onset disease via progerin-induced aging
Miller, J. D., Ganat, Y. M., Kishinevsky, S., Bowman, R. L., Liu, B., Tu, E. Y., Mandal, P. K., Vera, E., Shim, J.-W., Kriks, S., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.11.006 · Cited by 777
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.001 · Cited by 671
A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1
Funayama, M., Hasegawa, K., Kowa, H., Saito, M., Tsuji, S., & Obata, F. (2002) · Annals of Neurology · doi:10.1002/ana.10113 · Cited by 667
Prevalence of Parkinsonian Signs and Associated Mortality in a Community Population of Older People
Bennett, D. A., Beckett, L. A., Murray, A. M., Shannon, K. M., Goetz, C. G., Pilgrim, D. M., & Evans, D. A. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601113340202 · Cited by 659
Aging and Extrapyramidal Function
McGeer, P. L., McGeer, E. G., & Suzuki, J. S. (1977) · Archives of Neurology · doi:10.1001/archneur.1977.00500130053010 · Cited by 647
Epidemiology of parkinson’s disease
Tanner, C. M., & Goldman, S. M. (1996) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70259-0 · Cited by 640
Choi, H. K., Liu, S., & Curhan, G. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20761 · Cited by 595
Depression in Parkinson disease—epidemiology, mechanisms and management
Aarsland, D., Påhlhagen, S., Ballard, C. G., Ehrt, U., & Svenningsson, P. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.189 · Cited by 593
The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis
Hirsch, L., Jette, N., Frolkis, A., Steeves, T., & Pringsheim, T. (2016) · Neuroepidemiology · doi:10.1159/000445751 · Cited by 571
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains
Gegg, M. E., Burke, D., Heales, S. J. R., Cooper, J. M., Hardy, J., Wood, N. W., & Schapira, A. H. V. (2012) · Annals of Neurology · doi:10.1002/ana.23614 · Cited by 564
LRRK2 activation in idiopathic Parkinson’s disease
Di Maio, R., Hoffman, E. K., Rocha, E. M., Keeney, M. T., Sanders, L. H., De Miranda, B. R., Zharikov, A., Van Laar, A., Stepan, A. F., Lanz, T. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5429 · Cited by 564
Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease
Li, Y., Liu, W., Oo, T. F., Wang, L., Tang, Y., Jackson-Lewis, V., Zhou, C., Geghman, K., Bogdanov, M., Przedborski, S., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2349 · Cited by 536
Lill, C. M., Roehr, J. T., McQueen, M. B., Kavvoura, F. K., Bagade, S., Schjeide, B.-M. M., Schjeide, L. M., Meissner, E., Zauft, U., Allen, N. C., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002548 · Cited by 529
Zecca, L., Stroppolo, A., Gatti, A., Tampellini, D., Toscani, M., Gallorini, M., Giaveri, G., Arosio, P., Santambrogio, P., Fariello, R. G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403495101 · Cited by 495
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., Cooper, A., Garner, B., & Halliday, G. M. (2014) · Brain · doi:10.1093/brain/awt367 · Cited by 475
Neuropathology provides clues to the pathophysiology of Gaucher disease
Wong, K., Sidransky, E., Verma, A., Mixon, T., Sandberg, G. D., Wakefield, L. K., Morrison, A., Lwin, A., Colegial, C., Allman, J. M., et al. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.04.011 · Cited by 452
Genetics in Parkinson disease: Mendelian versus non‐Mendelian inheritance
Hernandez, D. G., Reed, X., & Singleton, A. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13593 · Cited by 448
Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses
Bellou, V., Belbasis, L., Tzoulaki, I., Evangelou, E., & Ioannidis, J. P. A. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.12.008 · Cited by 426
LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1
Wang, X., Yan, M. H., Fujioka, H., Liu, J., Wilson-Delfosse, A., Chen, S. G., Perry, G., Casadesus, G., & Zhu, X. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds003 · Cited by 424
Zecca, L., Gallorini, M., Schünemann, V., Trautwein, A. X., Gerlach, M., Riederer, P., Vezzoni, P., & Tampellini, D. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00186.x · Cited by 401
Occurrence of Parkinson's syndrome in type 1 Gaucher disease
Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B., & Zimran, A. (1996) · QJM · doi:10.1093/qjmed/89.9.691 · Cited by 401
Chu, Y., & Kordower, J. H. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.021 · Cited by 396
Deciphering the role of heterozygous mutations in genes associated with parkinsonism
Klein, C., Lohmann-Hedrich, K., Rogaeva, E., Schlossmacher, M. G., & Lang, A. E. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70174-6 · Cited by 309
Calcium, ageing, and neuronal vulnerability in Parkinson's disease
Surmeier, D. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70246-6 · Cited by 297
Striatal dopamine deficiency in parkinson's disease: Role of aging
Scherman, D., Desnos, C., Darchen, F., Pollak, P., Javoy‐Agid, F., & Agid, Y. (1989) · Annals of Neurology · doi:10.1002/ana.410260409 · Cited by 286
Head injury and risk of Parkinson disease: A systematic review and meta‐analysis
Jafari, S., Etminan, M., Aminzadeh, F., & Samii, A. (2013) · Movement Disorders · doi:10.1002/mds.25458 · Cited by 282
Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease
Goris, A., Williams‐Gray, C. H., Clark, G. R., Foltynie, T., Lewis, S. J. G., Brown, J., Ban, M., Spillantini, M. G., Compston, A., Burn, D. J., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21192 · Cited by 270
Aging and Parkinson's disease: Different sides of the same coin?
Collier, T. J., Kanaan, N. M., & Kordower, J. H. (2017) · Movement Disorders · doi:10.1002/mds.27037 · Cited by 268
Occupation and Risk of Parkinsonism: A Multicenter Case-Control Study
Tanner, C. M., Ross, G. W., Jewell, S. A., Hauser, R. A., Jankovic, J., Factor, S. A., Bressman, S., Deligtisch, A., Marras, C., Lyons, K. E., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.195 · Cited by 267
Genetic risk factors in Parkinson’s disease
Billingsley, K. J., Bandres-Ciga, S., Saez-Atienzar, S., & Singleton, A. B. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2817-y · Cited by 249
Nicotine as a potential neuroprotective agent for Parkinson's disease
Quik, M., Perez, X. A., & Bordia, T. (2012) · Movement Disorders · doi:10.1002/mds.25028 · Cited by 242
Breckenridge, C. B., Berry, C., Chang, E. T., Sielken, R. L., & Mandel, J. S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151841 · Cited by 239
Self-citationAdvances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems
Brichta, L., Greengard, P., & Flajolet, M. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.06.003 · Cited by 223
Mutations for Gaucher Disease Confer High Susceptibility to Parkinson Disease
Mitsui, J., Mizuta, I., Toyoda, A., Ashida, R., Takahashi, Y., Goto, J., Fukuda, Y., Date, H., Iwata, A., Yamamoto, M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.72 · Cited by 209
Ho, P. W.-L., Leung, C.-T., Liu, H., Pang, S. Y.-Y., Lam, C. S.-C., Xian, J., Li, L., Kung, M. H.-W., Ramsden, D. B., & Ho, S.-L. (2020) · Autophagy · doi:10.1080/15548627.2019.1603545 · Cited by 207
Self-citationAge‐related decreases in Nurr1 immunoreactivity in the human substantia nigra
Chu, Y., Kompoliti, K., Cochran, E. J., Mufson, E. J., & Kordower, J. H. (2002) · Journal of Comparative Neurology · doi:10.1002/cne.10261 · Cited by 199
Temporal relationship between cigarette smoking and risk of Parkinson disease
Thacker, E. L., O’Reilly, E. J., Weisskopf, M. G., Chen, H., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., & Ascherio, A. (2007) · Neurology · doi:10.1212/01.wnl.0000256374.50227.4b · Cited by 194
Evans, A. H. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.065417 · Cited by 185
Ito, G., Katsemonova, K., Tonelli, F., Lis, P., Baptista, M. A. S., Shpiro, N., Duddy, G., Wilson, S., Ho, P. W.-L., Ho, S.-L., et al. (2016) · Biochemical Journal · doi:10.1042/bcj20160557 · Cited by 183
Self-citationCasarejos, M. J., Menéndez, J., Solano, R. M., Rodríguez‐Navarro, J. A., de Yébenes, J. G., & Mena, M. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03777.x · Cited by 178
Advances in Parkinson’s Disease: 200 Years Later
del Rey, N. L., Quiroga‐Varela, A., Garbayo, E., Carballo‐Carbajal, I., Fernández‐Santiago, R., Monje, M. H. G., Trigo‐Damas, I., Blanco‐Prieto, M. J., & Blesa, J. (2018) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2018.00113 · Cited by 177
Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
Sardi, S. P., Cedarbaum, J. M., & Brundin, P. (2018) · Movement Disorders · doi:10.1002/mds.27414 · Cited by 170
Sugama, S., Yang, L., Cho, B. P., DeGiorgio, L. A., Lorenzl, S., Albers, D. S., Beal, M. F., Volpe, B. T., & Joh, T. H. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04085-4 · Cited by 164
Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium
Marder, K., Wang, Y., Alcalay, R. N., Mejia-Santana, H., Tang, M.-X., Lee, A., Raymond, D., Mirelman, A., Saunders-Pullman, R., Clark, L., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001708 · Cited by 161
Parkinson disease and smoking revisited: Ease of quitting is an early sign of the disease
Ritz, B., Lee, P.-C., Lassen, C. F., & Arah, O. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000879 · Cited by 160
Lis, P., Burel, S., Steger, M., Mann, M., Brown, F., Diez, F., Tonelli, F., Holton, J. L., Ho, P. W., Ho, S.-L., et al. (2018) · Biochemical Journal · doi:10.1042/bcj20170802 · Cited by 151
Self-citationStafa, K., Tsika, E., Moser, R., Musso, A., Glauser, L., Jones, A., Biskup, S., Xiong, Y., Bandopadhyay, R., Dawson, V. L., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt600 · Cited by 148
Exercise: Is it a neuroprotective and if so, how does it work?
Zigmond, M. J., & Smeyne, R. J. (2013) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70030-0 · Cited by 144
The role of monogenic genes in idiopathic Parkinson’s disease
Reed, X., Bandrés‐Ciga, S., Blauwendraat, C., & Cookson, M. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.11.012 · Cited by 143
Increased incidence of Parkinson disease among relatives of patients with Gaucher disease
Halperin, A., Elstein, D., & Zimran, A. (2006) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2006.02.004 · Cited by 138
Unbiased morphometrical measurements show loss of pigmented nigral neurones with ageing
Ma, Röytt, Collan, & Rinne (1999) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1999.00202.x · Cited by 136
Rugbjerg, K., Ritz, B. R., Korbo, L., Martinussen, N., & Olsen, J. H. (2008) · BMJ · doi:10.1136/bmj.a2494 · Cited by 131
Histological changes of the dopaminergic nigrostriatal system in aging
Stark, A. K., & Pakkenberg, B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0972-9 · Cited by 123
Concordance for Parkinson's disease in twins: A 20‐year update
Goldman, S. M., MAREK, K. L., Ottman, R., Meng, C., Comyns, K., Chan, P., Ma, J., Marras, C., Langston, J. W., Ross, G. W., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25441 · Cited by 123
Glucocerebrosidase mutations and the pathogenesis of Parkinson disease
Beavan, M. S., & Schapira, A. H. V. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.849003 · Cited by 122
The tau H2 haplotype is almost exclusively Caucasian in origin
Evans, E. W., Fung, H., Steele, J. C., Eerola, J., Tienari, P. J., Pittman, A. M., de Silva, R., Myers, A., Vrièze, F. W., Singleton, A., et al. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.05.119 · Cited by 120
LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism
Arranz, A. M., Delbroek, L., Van Kolen, K., Guimarães, M. R., Mandemakers, W., Daneels, G., Matta, S., Calafate, S., Shaban, H., Baatsen, P., et al. (2014) · Journal of Cell Science · doi:10.1242/jcs.158196 · Cited by 111
Biomarkers of cognitive decline in Parkinson's disease
Lin, C., & Wu, R. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.02.010 · Cited by 111
Delaying aging is neuroprotective in Parkinson’s disease: a genetic analysis in C. elegans models
Cooper, J. F., Dues, D. J., Spielbauer, K. K., Machiela, E., Senchuk, M. M., & Raamsdonk, J. M. V. (2015) · npj Parkinson s Disease · doi:10.1038/npjparkd.2015.22 · Cited by 109
Longo, F., Mercatelli, D., Novello, S., Arcuri, L., Brugnoli, A., Vincenzi, F., Russo, I., Berti, G., Mabrouk, O. S., Kennedy, R. T., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0426-8 · Cited by 109
The endosomal pathway in Parkinson's disease
Perrett, R. M., Alexopoulou, Z., & Tofaris, G. K. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.02.009 · Cited by 104
The Evolution of Genetics: Alzheimer’s and Parkinson’s Diseases
Singleton, A., & Hardy, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.040 · Cited by 100
Helley, M., Pinnell, J. R., Sportelli, C., & Tieu, K. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00177 · Cited by 99
Marras, C., Hincapié, C. A., Kristman, V. L., Cancelliere, C., Soklaridis, S., Li, A., Borg, J., af Geijerstam, J.-L., & Cassidy, J. D. (2014) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2013.08.298 · Cited by 98
Differential effects of exercise intensity on serum uric acid concentration
Green, H. J., & Fraser, I. (1988) · Medicine & Science in Sports & Exercise · doi:10.1249/00005768-198802000-00008 · Cited by 89
Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration
Kachroo, A., Irizarry, M. C., & Schwarzschild, M. A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.02.007 · Cited by 88
Kanaan, N. M., Kordower, J. H., & Collier, T. J. (2007) · The Journal of Comparative Neurology · doi:10.1002/cne.21333 · Cited by 83
Matsui, H., Kenmochi, N., & Namikawa, K. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.015 · Cited by 75
Kanaan, N. M., Kordower, J. H., & Collier, T. J. (2008) · Glia · doi:10.1002/glia.20690 · Cited by 73
Environmental tobacco smoke and Parkinson's disease
Nielsen, S. S., Gallagher, L. G., Lundin, J. I., Longstreth, W. T., Smith‐Weller, T., Franklin, G. M., Swanson, P. D., & Checkoway, H. (2011) · Movement Disorders · doi:10.1002/mds.24012 · Cited by 70
Bakshi, R., Zhang, H., Logan, R. A., Joshi, I., Xu, Y., Chen, X., & Schwarzschild, M. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.022 · Cited by 69
Head injury and Parkinson's disease: A population‐based study
Fang, F., Chen, H., Feldman, A. L., Kamel, F., Ye, W., & Wirdefeldt, K. (2012) · Movement Disorders · doi:10.1002/mds.25143 · Cited by 63
Smokeless tobacco use and the risk of Parkinson's disease mortality
O’Reilly, É. J., McCullough, M. L., Chao, A., Henley, S. J., Calle, E. E., Thun, M. J., & Ascherio, A. (2005) · Movement Disorders · doi:10.1002/mds.20587 · Cited by 61
Head injury at early ages is associated with risk of Parkinson's disease
Taylor, K. M., Saint‐Hilaire, M., Sudarsky, L. R., Simon, D. K., Hersh, B. P., Sparrow, D., Hu, H., & Weisskopf, M. G. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.12.005 · Cited by 57
Brain aging: A Ianus‐faced player between health and neurodegeneration
Vanni, S., Baldeschi, A. C., Zattoni, M., & Legname, G. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24379 · Cited by 57
Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease
Liu, H., Ho, P. W., Leung, G. C.-T., Lam, C. S.-C., Pang, S. Y.-Y., Li, L., Kung, M. H.-W., Ramsden, D. B., & Ho, S. (2017) · Scientific Reports · doi:10.1038/srep40887 · Cited by 56
Self-citationLiu, X., & Klionsky, D. J. (2017) · Autophagy · doi:10.1080/15548627.2017.1386821 · Cited by 56
Kanaan, N. M., Kordower, J. H., & Collier, T. J. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06307.x · Cited by 52
Redenšek, S., Trošt, M., & Dolžan, V. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00020 · Cited by 52
Yu, Z., Wang, T., Xu, J., Wang, W., Wang, G., Chen, C., Zheng, L., Li, P., Gong, D., Li, X., et al. (2014) · Journal of Human Genetics · doi:10.1038/jhg.2014.110 · Cited by 43
LRRK 2 R1441G mice are more liable to dopamine depletion and locomotor inactivity
Liu, H., Song, L., Ho, P. W., Tse, H., Pang, S. Y., Kung, M. H.-W., Ho, J. W.-M., Ramsden, D. B., Zhou, Z., & Ho, S. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.45 · Cited by 43
Self-citationMechanisms of Mutant LRRK2 Neurodegeneration
Cookson, M. R. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-49969-7_12 · Cited by 42
Passive smoking and Parkinson disease
Mellick, G. D., GARTNER, C. E., Silburn, P. A., & Battistutta, D. (2006) · Neurology · doi:10.1212/01.wnl.0000223618.53129.56 · Cited by 41
Huang, C., Chou, Y. W., Lai, S. ‐., Chang, H. ‐., Yeh, T. ‐., Weng, Y.-H., Chen, R. ‐., Huang, Y., & Lu, C. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03362.x · Cited by 38
Chen, E., Kallwitz, E. R., Leff, S. E., Cochran, E. J., Mufson, E. J., Kordower, J. H., & Mandel, R. J. (2000) · The Journal of Comparative Neurology · doi:10.1002/1096-9861(20001030)426:4<534::aid-cne3>3.0.co;2-g · Cited by 34
The Changing Landscape of Parkinson Epidemiologic Research
Chen, H. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171238 · Cited by 32
Tsuji, T., Asanuma, M., Miyazaki, I., Miyoshi, K., & Ogawa, N. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9863-x · Cited by 27
Cited by
The role of histone modifications: from neurodevelopment to neurodiseases
Park, J., Lee, K., Kim, K., & Yi, S.-J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01078-9 · Cited by 297
NLRP3 inflammasome in neuroinflammation and central nervous system diseases
Xu, W., Huang, Y., & Zhou, R. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01275-w · Cited by 295
Borghammer, P. (2021) · Journal of Parkinson's Disease · doi:10.3233/jpd-202481 · Cited by 259
Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595635 · Cited by 129
Mitochondrial dysfunction in astrocytes: A role in Parkinson’s disease?
Bantle, C. M., Hirst, W. D., Weihofen, A., & Shlevkov, E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.608026 · Cited by 95
Metadata
- Authors
- Pang, S. Y.-Y., Ho, P. W.-L., Liu, H.-F., Leung, C.-T., Li, L., Chang, E. E. S., Ramsden, D. B., & Ho, S.-L.
- Venue
- Translational Neurodegeneration
- Published
- 2019-08-16
- Volume
- 8
- Issue
- 1
- Pages
- 23-23
- ISSN
- 2047-9158 (ISSN-L)
- OpenAlex
- W2968035162
- Cited by
- 427
- References
- 111
- FWCI
- 19.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.